A JACC FLOW trial subgroup analysis confirms semaglutide protects kidneys in T2D and CKD patients regardless of cardiovascular status. Here’s what the new evidence means.
JACC Study Confirms Semaglutide Provides Kidney Protection for Adults with Type 2 Diabetes and CKD
by | Jul 22, 2026 | Uncategorized | 0 comments
Recent Comments